

JPET#163014

Serotonin receptors in rat jugular vein: presence and involvement in the contraction

A. Elizabeth Linder, Geri L. Gaskell, Theodora Szasz, Janice M. Thompson and
Stephanie W. Watts

Department of Pharmacology and Toxicology (G.L.G.; T.S.; J.M.T.; S.W.W.), Michigan State University, East Lansing, MI, 48824, USA and Department of Pharmacology (A.E.L.), Biological Sciences Center, Universidade Federal de Santa Catarina, Florianopolis, SC, 88049-900, Brazil

JPET#163014

Running Title

Contractile 5-HT receptors in jugular vein

A. Elizabeth Linder

Department of Pharmacology

Universidade Federal de Santa Catarina

University Campus, Trindade

Biological Sciences Centre, Block "D"

88049-900 Florianopolis, Santa Catarina, Brazil

Phone: 55 (48) 3721.9491

Fax: 55 (48) 3337.5479

Email: beth.linder@ccb.ufsc.br

Text pages: 34

Tables: 1

Figures: 6

References: 47

Abstract: 250

Introduction: 573

Discussion: 1.481

Recommended section: Cardiovascular

JPET#163014

List of Abbreviations

- 5-HT: 5-hydroxytryptamine; serotonin
- 5-CT: 5-carboxamidotryptamine
- 8-OH-DPAT: (\pm)-2-dipropyl-amino-8-hydroxyl-1,2,3,4-tetrahydronaphthalene
- α -methyl-5-HT: alpha-methyl-5-hydroxytryptamine
- BRL54443: 5-hydroxy-3-(1-methylpiperidin-4-yl)-1H-indole
- BW723C86: [(alpha-methyl-5-(2-thienylmethoxy)-1H-indole-3-ethanamine)]
- DOI: (\pm)-2,5-dimethoxy-(-)-4-iodo-2,5-dimethoxyphenylisopropylamine
- EMD386088: 5-chloro-2-methyl-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole hydrochloride
- GR127935: 2-methyl-4-(5-methyl-[1,2,4]oxadiazol-3-yl)-biphenyl-4-carboxylic-acid[4-methoxy-3-(4-methyl-piperazin-1-yl)-phenyl]amide
- ketanserin: [3-[2-[4-(4-fluoro benzoyl)-piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione]
- LP44: {4-[2-(methylthio)phenyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-1-piperazinehexanamide hydrochloride}
- LY 266097: (1-(2-chloro-3,4-dimethoxybenzyl)-6-methyl-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole hydrochloride)
- MAO: monoamine oxidase
- PGF_{2 α} : prostaglandin F2 alpha
- RU24696: 5-methoxy-3 (1,2,3,6-tetrahydropyridin-4-yl) (1H indole)
- SB269970: (2R)-1-[(3-hydroxyphenyl)sulfonyl]-2-[2-(4-mentyl-1-piperidinyl)ethyl]pyrrolidine hydrochloride

JPET#163014

- sumatriptan: [1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide]
- WAY100135: [[O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide]
- Zacopride: 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxybenzamide

JPET#163014

Abstract

Serotonin (5-hydroxytryptamine; 5-HT) is released during platelet aggregation, a phenomenon commonly observed in blood clot formation and venous diseases. Once released, 5-HT can interact with its receptors in the peripheral vasculature to modify vascular tone. The goal of this study was to perform a detailed pharmacological characterization of the 5-HT receptors involved in the contractile response of the rat jugular vein (RJV) using recently developed drugs with greater selectivity towards 5-HT receptor subtypes. We hypothesized that, as for other blood vessels, the 5-HT_{1B/1D} and 5-HT_{2B} receptor subtypes mediate contraction in RJV alongside the 5-HT_{2A} receptor subtype. Endothelium-intact RJV rings were set up in an isolated organ bath for isometric tension recordings and contractile concentration-effect curves were obtained for 13 distinct serotonergic receptor agonists. Surprisingly, the 5-HT_{1A} and the mixed 5-HT_{1A/1B} receptor agonists 8-OH-DPAT and RU24969 caused contractions that were antagonized by the 5-HT_{1A} receptor antagonist WAY100135. The contractile curve to 5-HT was shifted to the right by WAY100135, ketanserin (5-HT_{2A/C} receptor antagonist) and LY266097 (5-HT_{2B} receptor antagonist). Ketanserin also caused rightward shifts of the contractile curves to 8-OH-DPAT, RU24969 and the 5-HT_{2B} receptor agonist BW723C86. Agonists for 5-HT_{1B/1D/1F}, 5-HT₃, 5-HT₆ and 5-HT₇ receptors were inactive. In real time PCR experiments that have never been performed in this tissue previously, we observed mRNA expression for the 5-HT_{2A}, 5-HT_{2B} and 5-HT₇ receptors, whereas no significant mRNA expression was found for 5-HT_{1A}, 5-HT_{1B} and 5-HT_{1D} receptors. These results support the 5-HT_{2A} receptor as the main subtype targeted by 5-HT to contract the RJV.

JPET#163014

Introduction

Serotonin (5-hydroxytryptamine; 5-HT) was first described as a substance with the ability to increase smooth muscle tone (Vialli and Erspamer, 1937; Rapport et al., 1948). 5-HT is synthesized by the enterochromaffin cells and released into the circulation. In the periphery, platelets are the largest store for 5-HT. Interestingly, our laboratory recently showed that peripheral vasculature has the ability to synthesize, take up and metabolize 5-HT (Linder et al., 2008; Ni et al., 2008). Moreover, the amount of 5-HT measured in veins is comparatively higher than in arteries, suggesting that peripheral veins may also constitute important stores of the amine (Linder et al., 2008). Thus, by controlling the amount of 5-HT within the peripheral vasculature environment, veins may exert relevant roles in adjusting vascular tone.

5-HT is among the mediators released during platelet aggregation, a process frequently observed in venous diseases, such as deep vein thrombosis and varicose veins (Ficarelli et al., 2008; Bailey et al., 2009). Although venous diseases may affect and decrease the quality of life up to a quarter of the adult population (Lim et al., 2008), veins have attracted relatively little attention in terms of studies in the cardiovascular field. Once released, 5-HT can be taken up by peripheral tissues (Linder et al., 2008; Ni et al., 2008; Linder et al., 2009) or interact with its receptors in target tissues to induce its actions. The contraction induced by 5-HT is increased in the human varicose spermatic vein during varicocele, a venous disease (Yildiz et al., 2003).

Traditionally, the physiological actions of 5-HT are mediated by seven families of 5-HT receptors (5-HT₁-5-HT₇), with at least 15 different subtypes (Hoyer et al., 1994). The main 5-HT receptors responsible for modifying vascular tone are the 5-HT₁, 5-HT₂,

JPET#163014

and 5-HT₇ receptors. In many arterial beds such as the rat and mouse aorta, the 5-HT_{2A} receptor is the primary receptor mediating 5-HT-induced contraction (McKune and Watts, 2001; Russell et al., 2002). Most of these findings were supported by pharmacological studies showing that agonists such as (±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI) and α-methyl-5-HT induce arterial contractions which are antagonized by ketanserin. In addition to the 5-HT_{2A} receptor, the 5-HT_{1B/1D} receptor and 5-HT_{2B} receptor are also involved in 5-HT-induced arterial smooth muscle contraction (Kaumann et al., 1993; Morecroft et al., 1999; Banes and Watts, 2002; Gul et al., 2003; Watts and Thompson, 2004).

Previous studies suggest that 5-HT contracts the rat jugular vein mainly by 5-HT_{2A} receptor subtype activation (Cohen et al., 1981; Cushing and Cohen, 1992). However, 5-HT receptors such as the 5-HT₆ and 5-HT₇ receptors were sequenced only after these studies. Additionally, despite the development of many more selective 5-HT receptor ligands since the publication of those studies, such drugs have not yet been used to better characterize the 5-HT receptor population present in the rat jugular vein. Understanding the receptor targets of 5-HT in veins may be of relevance for the treatment of venous diseases. Therefore, the present study was undertaken to further characterize the 5-HT receptors subtypes implicated in constriction of the rat isolated endothelium-intact jugular vein, by testing the effects of some of these newer pharmacological tools in classical functional assays of isometric tension carried out in organ baths, allied to SYBR-Green based real time PCR, a technique never employed in this tissue before. We hypothesized that in addition to the 5-HT_{2A} receptor, the 5-

JPET#163014

HT_{1B/1D} and 5HT_{2B} receptor subtypes are also involved in mediating contraction to 5-HT
in the jugular vein from the rat.

JPET#163014

Methods

Animal Use

Male Sprague-Dawley rats (250–300 g; Charles River Laboratories, Inc., Portage, MI) were maintained on a 12h light/dark cycle with free access to rat chow and water. On the day of the experiment, rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and both jugular veins were excised. All procedures involving animal use were performed in accordance with the Institutional Animal Use and Care Committee of Michigan State University.

In Vitro Measurement of Isometric Force Generation in Jugular Vein Rings

After removal of fat and connective tissue, endothelium-intact rings (2-4 mm long) from the proximal jugular vein (before bifurcation) were mounted in an organ chamber for isometric tension recordings and bathed in physiological salt solution (PSS) of the following composition in mM: NaCl 130.0, KCl 4.7, KH₂PO₄ 1.2, MgSO₄ 1.2, CaCl₂ 1.6, NaHCO₃ 14.9, EDTA 0.03, glucose 5.5 which was maintained at 37°C and bubbled with 95% O₂ and 5% CO₂. The jugular vein rings were set gradually at 1.0 g passive tension (optimum passive tension). After a 1-hour equilibration period, vessels were contracted with potassium chloride (KCl 60 mM) to test tissue viability. Only tissues that contracted 150 mg or more were included in this study. The tissues were rinsed with PSS to wash out KCl and to return to baseline before being challenged with PGF_{2α} (1 μM).

JPET#163014

Preliminary data showed that the contraction induced by this concentration of PGF_{2α} is easily reversed upon washout and reproducible when rings are challenged at 30-min intervals (first challenge 285.5 ± 65.9 mg; second challenge 364.4 ± 58.2 mg; n=6; P ≥ 0.05). The integrity of the endothelium was evaluated by the ability of acetylcholine (Sigma Chemicals, St Louis, MO, USA; 10 μM) to relax PGF_{2α}-contracted jugular vein rings. Only rings that relaxed 70% or more to acetylcholine were included in this study. One of the following protocols was then followed.

Response to 5-HT receptor agonists:

Increasing concentrations of 5-HT (Sigma Chemicals, St Louis, MO, USA), α-methyl-5-HT, 5-methoxytryptamine, 8-OH-DPAT, RU 24969, sumatriptan, 5-CT, BRL 54443, BW 723C86, zacopride, EMD 386088, LP44 or DOI were added cumulatively to the organ bath in the concentration range of 1 nM to 10 μM in order to obtain a concentration-effect curve (CEC) to the agonist in study. Each jugular vein ring was used to obtain concentration-response curves to two agonists. In most cases, agonist assignment to any given preparation, as well as the order in which each of the curves was to be obtained (at 60-min intervals), was randomized. As the magnitude of the contractions induced by each of these agonists was similar when employed to generate the first or second curve, the data concerning each one was pooled. Importantly, however, BW 723C86 and α-methyl-5-HT were always used as the second agonist due to the difficulty in washing out their effects upon completion of the curve, as previously described (Watts and Thompson, 2004).

JPET#163014

Influence of receptor antagonists on contractions induced by 5-HT receptor agonists:

To assess the possible contribution of 5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A/2C}, 5-HT_{2B} and 5-HT₇ receptors to contractions induced by 5-HT, concentration-response curves to 5-HT (1 nM to 10 μM) were obtained in absence or in presence of their selective antagonists WAY 100135 (0.1, 0.3 μM), GR 127935 (3, 10 nM), ketanserin (30 nM), LY266097 (10, 30 nM) and SB269970 (10, 30 nM), respectively.

In most cases, two consecutive curves to 5-HT were obtained at a 1-h interval, with the antagonist being added 30 min after completion of the first control curve and restoration of tension to baseline values (by multiple rinses). In such cases, the antagonist was incubated for 30 min prior to initiation of the second curve. Control preparations were incubated solely with the corresponding volume of deionized water (the vehicle used to prepare antagonists), to check for potential vehicle effects or spontaneous changes in responsiveness. For ketanserin, concentration-response curves to 5-HT were performed after a 30-min incubation with ketanserin (30 nM) and compared to the responses induced by 5-HT in rings in which ketanserin was omitted.

The same type of protocol (i.e. 30 min incubation with antagonist prior to the second curve) was also employed to evaluate the susceptibility of the contractile effects of the 5-HT_{1A} receptor agonist 8-OH-DPAT and the mixed 5-HT_{1A/1B} receptor agonist RU24969 to antagonism by the 5-HT_{1A} and 5-HT_{2A} receptor antagonists WAY 100135 and ketanserin, respectively. However, because contractions induced by the 5-HT_{2B} receptor agonist BW723C86 are largely resistant to washout, the antagonistic effects of the selective 5-HT_{1B} receptor antagonist LY266097 (10 nM) or ketanserin (30 nM) on

JPET#163014

concentration-response curves to this agonist were evaluated by comparing single curves obtained for the agonist in distinct preparations incubated (for 30 min) with the antagonist or its vehicle. The concentrations of all antagonists used were chosen based on their affinities for the receptors of interest.

RNA isolation, reverse transcription, and real time PCR

Total RNA from ~10-mg sections of endothelium-intact jugular vein was isolated using the MELT total RNA isolation system (Ambion/Applied Biosystems, Austin, TX) and quantified on a Nanodrop spectrophotometer. One microgram of DNase-treated total RNA from each sample was reverse-transcribed using an oligo(dT)₁₂₋₁₈ primer, dNTP mix, and SuperScript II reverse transcriptase (Invitrogen) according to the manufacturer's protocol. Primers for RNA encoding the rat 5-HT receptor subtypes 5-HT_{1A}, 5-HT_{1B}, 5-HT_{1D}, 5-HT_{2A}, 5-HT_{2B} and 5-HT₇ and for rat β -2-microglobulin (β 2m) were purchased from SuperArray (Frederick, MD). This gene has previously been used for comparative real-time gene expression studies (Wacker and Godard, 2005; Linder et al., 2008). Quantification of 5-HT receptors and β 2m amplification products was performed using the respective primers (0.1 μ M) and the SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) in the 7500 Real-Time PCR System (Applied Biosystems), according to the manufacturer's protocol. For each reaction, the cycle threshold (Ct) value was determined as the cycle number at which the fluorescence value reached the threshold level, which was set above the background fluorescence in

JPET#163014

the exponential phase of the real-time amplification curves. A dissociation curve was performed at the end of each run to ensure that a single product was amplified.

Materials

The drugs were ultimately diluted in deionized water on the day of the experiment from stock solutions diluted in the appropriate vehicle. 5-HT creatinine sulfate, BW723C86, 8-OH-DPAT, α -methyl-5-HT, 5-methoxytryptamine, DOI, acetylcholine chloride and ketanserin tartrate were purchased from Sigma-Aldrich. α -methyl-5-HT, 5-CT, BRL54443, zacopride, RU24696, EMD386088, WAY100135, SB269970, LP44 and GR127935 were purchased from TOCRIS Bioscience (Ellisville, MO, USA). Sumatriptan was purchased from GlaxoSmithKline (Stevenage, Hertfordshire, UK), and PGF_{2 α} from Cayman Chemicals Company (Ann Arbor, MI, USA). LY266097 was kindly provided by Eli Lilly & Co. (Indianapolis, IN).

Data Analysis

Results concerning intensities of isometric contraction were measured in mg of force generated and shown as percentages of the initial response to KCl (60 mM), and expressed as mean \pm standard error of the mean (SEM). KCl (60mM) produced 244.0 \pm 9.3 mg of force (n=54) in the rat jugular vein. Sensitivity to agonists is expressed as pD₂ values (-log EC₅₀) calculated by non-linear regression in GraphPad Prism (GraphPad Software Inc., San Diego, CA), where EC₅₀ is the effective molar concentration of the agonist that induces 50% of the maximal response. When a maximal contraction was

JPET#163014

not clearly obtained, the estimated EC₅₀ value is possibly smaller than the true EC₅₀. Apparent antagonist dissociation constants (apparent K_B values, reported as pK_B) were calculated using the following formula: $\log K_B = \log (dr-1) - \log [B]$, where dr indicates the ratio between the EC₅₀ values of the agonist obtained in presence and absence of antagonist, and [B] corresponds to antagonist concentration. The relative quantification of the 5-HT receptors to β 2m mRNA was expressed as $2^{-\Delta Ct}$, where ΔCt is the difference in cycle threshold between the 5-HT receptor gene and the housekeeping gene β 2m. Data were analyzed by Student's t-test for paired or unpaired comparisons, as appropriate. Additional statistical analyses were performed using 1-way ANOVA followed by the Student-Newman-Keuls post hoc test for multiple comparisons. A value of P < 0.05 was considered statistically significant.

JPET#163014

Results

Effect of serotonergic receptor agonists

Figure 1A shows the concentration-effect curves to those 5-HT receptor agonists that are potent and induced an equivalent or larger maximal contractile response in rat jugular vein compared to 5-HT. Among these agonists are the non-selective 5-HT receptor agonists 5-CT and 5-methoxytryptamine, the non-selective 5-HT₂ receptor agonist α -methyl-5-HT, the partial 5-HT_{2A} receptor agonist DOI and the mixed 5-HT_{1F}/5-HT_{2A} receptor agonist BRL54443. Figure 1B shows the concentration-effect curve of the 5-HT receptor agonists that are less potent and induced a smaller contraction compared to 5-HT or no contraction in rat jugular vein. The 5-HT_{1A}, 5-HT_{1A/1B} and the 5-HT_{2B} receptor agonists, 8-OH-DPAT, RU24696 and BW723C86, respectively, induced a concentration-dependent contraction. On the other hand, sumatriptan (5-HT_{1B/1D/1F} receptor agonist), EMD 386088 (5-HT₆ receptor agonist), zacopride (5-HT₃ receptor agonist) and LP44 (5-HT₇ receptor agonist) failed to induce a concentration-effect curve in rat jugular vein rings. LP44 induced a contraction only at the highest concentration tested (10 μ M). Parameters of the sensitivity (pD_2) and potency (maximal effect) of these agonists are shown in Table 1.

Blockade by serotonergic receptor antagonists

Figure 2 shows that the concentration-effect curve induced by 5-HT is right-shifted in the presence of the 5-HT_{2A} receptor antagonist ketanserin (30 nM). To further investigate the additional putative 5-HT receptors involved in 5-HT-induced contraction

JPET#163014

in rat jugular vein, the contraction evoked by 5-HT was evaluated in the presence of antagonists of the 5-HT_{1A} (WAY100135), 5-HT_{1B} (GR127935), 5-HT_{2B} (LY266097) and 5-HT₇ (SB269970) receptors. Figure 3 shows the concentration effect curve to 5-HT in the absence and in the presence of these different 5-HT receptor antagonists. The 5-HT curve was shifted to the right in the presence of WAY100135 (0.3 μM; pK_B 6.75 ± 0.12) (Figure 3B), and LY266097 (10 nM and 30 nM; pK_B 8.1 ± 0.06) (Figure 3E/3F). The lowest concentration of WAY100135 (0.1 μM) (Figure 3A) was ineffective in modifying the concentration effect curve to 5-HT in the rat jugular vein. GR127935 (Figure 3C/3D) and SB269970 (Figure 3G/3H) had no effect on the contraction induced by 5-HT in rat jugular vein.

Contractions mediated by 5-HT_{1A} and 5-HT_{2B} receptors

To give further support to the involvement of the 5-HT_{1A} receptor in the contraction induced by 5-HT in rat jugular vein, the contractions induced by the 5-HT_{1A} and 5-HT_{1A/1B} receptor agonists 8-OH-DPAT and RU24969, respectively, were investigated in the presence of the 5-HT_{1A} antagonist WAY100135 (pK_B 6.46 ± 0.16 and 6.56 ± 0.07, respectively). The concentration-effect curves obtained with 8-OH-DPAT (Figure 4A) and RU24969 (Figure 4B) were shifted to the right in the presence of WAY100135 (0.3 μM). When WAY 100135 was replaced by vehicle, the concentration-effect curves induced by 8-OH-DPAT and RU24969 were comparable to the responses obtained in the absence of any treatment (data not shown).

To give further support to the involvement of the 5-HT_{2B} receptor in contraction, the contraction induced by the 5-HT_{2B} receptor agonist BW723C86 was investigated in the

JPET#163014

presence of the 5-HT_{2B} receptor antagonist LY266097. The maximum contraction induced by BW723C86 was impaired in the presence of the highest concentration of LY266097 (10 nM) and unaltered in the presence of the lowest concentration of LY266097 (0.5 nM) when compared to the contraction induced by BW723C86 in the absence of LY266097 (Figure 4C). LY266097 did not modify the potency of BW723C86.

The effect of ketanserin on the contraction induced by 8-OH-DPAT, RU24969 and BW723C86

To rule out the participation of 5-HT_{2A} receptors in the contraction induced by the 5-HT_{1A}, 5-HT_{1A/1B} and 5-HT_{2B} receptor agonists in the rat jugular vein, 8-OH-DPAT, RU24969 and BW723C86 were tested in the presence of ketanserin. Figure 5 shows that the contraction induced by all the agonists was abolished or dramatically reduced in the presence of ketanserin (30 nM) when compared to control curves in which ketanserin was absent.

mRNA expression of the 5-HT receptors in rat jugular vein

RNA from endothelium-intact jugular vein was isolated for measurements of 5-HT receptor mRNA expression by real time PCR. The value at which measurable product was first observed in real time PCR (cycle threshold values) was 16.4 ± 0.14 cycles for the housekeeping gene $\beta 2m$ in jugular vein (n =5). Figure 6 shows mRNA expression for 5-HT receptor subtypes relatively to mRNA expression for $\beta 2m$. mRNA expression was observed for 5-HT_{2A}, 5-HT_{2B} and 5-HT₇ receptors, but not for the 5-HT_{1A}, 5-HT_{1B} and 5-HT_{1D} receptors.

JPET#163014

Discussion

This work provides evidence for the presence of the 5-HT_{2A}, 5-HT_{2B} and 5-HT₇ receptors in endothelium-intact rat jugular vein rings. The endothelium was left intact to capture the greatest amount of physiologically relevant data as possible, even given potential confounding results of endothelial cell opposing smooth muscle cell function. By the judicious use of newly developed pharmacological tools, we show that the contraction induced by 5-HT in rat jugular vein is mainly mediated by 5-HT_{2A} receptor activation.

The 5-HT₁ receptors

From the 5-HT₁ receptor family, the subtypes 5-HT_{1B}, 5-HT_{1D} and 5-HT_{1F} have been found in blood vessels, as opposed to the 5-HT_{1A} receptor subtype which has been shown to be located at the central nervous system. Among these, the 5-HT_{1B} receptor is the predominant subtype in mediating contraction of vascular tissues (Bhattacharya et al., 2004). mRNA expression for the 5-HT_{1B} and 5-HT_{1D} receptors in vascular smooth muscle has been reported (Ullmer et al., 1995; Watts et al., 2001). In aorta from normotensive rats, 5-HT_{1B} receptor expression is not associated with contraction (Banes and Watts, 2001). We show here no pharmacological evidence for the involvement of 5-HT_{1B} receptor in the contraction induced by 5-HT in rat jugular vein. These findings were supported by the lack of RNA expression for this receptor subtype in this blood vessel. Functional and/or expression data did not support the involvement of 5-HT_{1D} and 5-HT_{1F} receptor subtypes in contracting rat jugular vein rings.

JPET#163014

The findings that the 5-HT_{1A} receptor agonist 8-OH-DPAT and the mixed 5-HT_{1A/1B} receptor agonist RU24969 induced contraction of rat jugular vein were unexpected. This would be the first evidence for 5-HT_{1A} receptor mediating contraction of vascular tissue, to our knowledge, despite reports of a central role for 5-HT_{1A} receptor on the control of cardiovascular function (Kuhn et al., 1980) and of the involvement of this receptor in mediating contractions of non-vascular tissues, such as the jejunum circular muscle (Delesalle et al., 2008) . However, when we further explored the serotonergic pharmacology of the rat jugular vein, we observed that the contractions induced by the so called “5-HT_{1A} receptor agonists” were inhibited by the 5-HT_{2A/2C} receptors antagonist ketanserin. It is important to highlight that ketanserin, at the concentration used in the present study, has less than 5% affinity for the rat 5-HT_{1A} receptor (Gozlan et al., 1983; Titeler et al., 1987). Additionally, the pD₂ values for 8-OH-DPAT and RU 24969 obtained in this study are closer to the values obtained for these agonists towards 5-HT_{2A} receptor rather than towards 5-HT_{1A} receptor (Hoyer et al., 1994). Along with the lack of RNA expression for 5-HT_{1A} receptor in the rat jugular vein, our results do not support a role for 5-HT_{1A} receptor in mediating contraction of the rat jugular vein.

5-HT₂ receptors

The 5-HT_{2A} receptor mediates the contraction induced by 5-HT in several human vascular beds including the pulmonary, mesenteric and coronary arteries, and the cutaneous and saphenous veins, (Bax et al., 1992; Bodelsson et al., 1992; Cortijo et al., 1997; Nilsson et al., 1999; Gul et al., 2003). In the rat, the 5-HT_{2A} receptor subtype is the main receptor activated by 5-HT to induce contraction in arteries such as aorta and

JPET#163014

mesenteric artery (Watts, 2002). Through the use of appropriate techniques, we show evidences to support that the contraction induced by 5-HT in the rat jugular vein is mainly due to 5-HT_{2A} receptor activation. These data give further support to a previous report by Cohen et al. (1981). However, compared to these studies performed earlier, the present findings were based on the knowledge of newest cloned receptors and making use of newest and more selective drugs towards 5-HT receptor subtypes. Whereas the involvement of the 5-HT_{2A} receptor on 5-HT-induced contraction of rat jugular vein is shown, we were unable to confirm the involvement of the 5-HT_{2B} receptor as a mediator of 5-HT-induced contraction of rat jugular vein regardless of its expression in this blood vessel. The pD₂ value for the 5-HT_{2B} agonist BW723C86 found here is closer to the value found for 5-HT_{2A} receptor rather than for 5-HT_{2B} receptor (Kitka and Bagdy, 2008). The pK_B value for the 5-HT_{2B} antagonist LY266097 we observed (~8) is similar to the one reported in rat jugular vein (Audia et al., 1996) and it is closer to the pK_B value of this antagonist towards 5-HT_{2A} receptor (7.7) rather than towards 5-HT_{2B} receptor (9.3) (Kitka and Bagdy, 2008). A contraction mediated by 5-HT_{2B} receptor activation was observed in aorta from hypertensive, but not from normotensive rats (Russell et al., 2002). Whereas this receptor was detected in endothelium-denuded vascular tissues (Banes and Watts, 2002; Watts and Thompson, 2004), 5-HT_{2B} receptor activation is associated with endothelium-dependent relaxation in porcine vena cava and pulmonary artery, as well as rabbit and rat jugular vein (Watts and Cohen, 1999). In unpublished data, we observed that 5-HT is unable to induce relaxation of rat jugular vein contracted with a prostaglandin mimetic agonist. Interestingly, Ellis et al. (1995) showed relaxation induced by 5-HT of contracted rat

JPET#163014

jugular vein only when the serotonergic receptors involved in contraction were inhibited by ketanserin (Ellis et al., 1995). In preliminary studies, we discovered that removing the endothelial cell from this blood vessel - without destroying the smooth muscle - is enormously difficult. Whether the 5-HT_{2B} receptor is functionally present mediating relaxation (dependent or not on the endothelium) in the rat jugular vein has yet to be investigated since mRNA expression may not always be mirrored by protein expression. Measurements of mRNA expression represent a useful tool to predict protein expression levels. However, a poor correlation between mRNA expression and protein expression can be found (Chen et al., 2002; Guo et al., 2008) as a consequence of a myriad of factors involving post-transcriptional events, post-translational modifications, variations in mRNA half-life and in protein stability, as well as technical imperfections ((Greenbaum et al., 2003). Further studies will be necessary to understand whether the highly expressed mRNA for the 5-HT_{2B} receptor is accompanied by the expression of a functional protein in the rat jugular vein.

The 5-HT_{2C} receptor was not given attention, since localization and function for this receptor in the cardiovascular system are still unknown (Villalon and Centurion, 2007).

5-HT₃, 5-HT₆, and 5-HT₇ receptors

We were unable to show through pharmacological approaches the involvement of 5-HT₃, 5-HT₆ and 5-HT₇ receptors in 5-HT-induced contraction of rat jugular vein.

Whereas the 5-HT₃ receptor is involved in cardiovascular responses to 5-HT (Villalon and Centurion, 2007), no reports for the involvement of the 5-HT₆ receptor in the cardiovascular system have been published to our knowledge. A role for the 5-HT₇

JPET#163014

receptor in the cardiovascular system has been shown [for review (Villalon and Centurion, 2007)]. No reports to date (including ours) have shown contraction induced by 5-HT₇ receptor activation. On the other hand, endothelium-independent relaxation mediated by 5-HT₇ receptor has been reported (Ishine et al., 2000; Jahnichen et al., 2005). Therefore, we cannot exclude the involvement of the 5-HT₇ receptor in relaxation of rat jugular vein; however this was not the aim of this study and it has yet to be tested.

In summary, the contractile data in combination with mRNA receptor expression support the conclusion that the 5-HT_{2A} receptor is the main receptor involved in 5-HT-induced contraction in rat jugular vein. However, a minor role for 5-HT_{2B} receptor cannot be ruled out. We are aware that our results intentionally pertain to the whole jugular vein, including smooth muscle and endothelium, according to the original intent of the present investigation. Whether mRNA expression for the 5-HT_{2B} and 5-HT₇ receptors is associated with a functional role, if any, in the rat jugular vein is a question that has yet to be explored.

Perspectives

Venous diseases have been recognized since old times as mentioned by Hippocrates (460–377 B.C.), and they currently may affect a quarter of the adult population (Lim et al., 2008). However, veins occupy only a marginal part of the total research in the cardiovascular field compared to arteries. Examples of venous diseases are the deep venous thrombosis and the human spermatic varicose vein. For the last one, increased

JPET#163014

vascular reactivity to 5-HT has been reported (Yildiz et al., 2003). On the other hand, an injury to the endothelium with a potential involvement of 5-HT may play an important role in the origin of deep venous thrombosis following platelet aggregation. Interestingly, the jugular vein can also be the target of a (although rare) septic thrombophlebitis followed by primary oropharyngeal infections, a venous disease known as Lemierre Syndrome (McMullan et al., 2004; Hile et al., 2009). Despite the development of animal models for studying venous hypertension (Pascarella et al., 2005) and venous diseases following vein grafts (Schachner et al., 2006), basic research has not yielded the significant advances in venous diseases that have been seen for other areas. We postulate that understanding the 5-HT pharmacology in veins may help navigate through the unknown avenues towards the treatment of venous diseases.

Acknowledgements

The authors are thankful to Dr. Giles A. Rae for his valuable comments.

JPET#163014

References

- Audia JE, Evrard DA, Murdoch GR, Droste JJ, Nissen JS, Schenck KW, Fludzinski P, Lucaites VL, Nelson DL and Cohen ML (1996) Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B (5HT2B) contractile receptor in the rat stomach fundus. *J Med Chem* **39**:2773-2780.
- Bailey AL, Scantlebury DC and Smyth SS (2009) Thrombosis and antithrombotic therapy in women. *Arterioscler Thromb Vasc Biol* **29**:284-288.
- Banes AK and Watts SW (2001) Enhanced contraction to 5-hydroxytryptamine is not due to "unmasking" of 5-hydroxytryptamine(1b) receptors in the mesenteric artery of the deoxycorticosterone acetate-salt rat. *Hypertension* **38**:891-895.
- Banes AK and Watts SW (2002) Upregulation of arterial serotonin 1B and 2B receptors in deoxycorticosterone acetate-salt hypertension. *Hypertension* **39**:394-398.
- Bax WA, Van Heuven-Nolsen D, Bos E, Simoons ML and Saxena PR (1992) 5-Hydroxytryptamine-induced contractions of the human isolated saphenous vein: involvement of 5-HT2 and 5-HT1D-like receptors, and a comparison with grafted veins. *Naunyn Schmiedebergs Arch Pharmacol* **345**:500-508.
- Bhattacharya A, Schenck KW, Xu YC, Nisenbaum L, Galbreath E and Cohen ML (2004) 5-Hydroxytryptamine1B receptor-mediated contraction of rabbit saphenous vein and basilar artery: role of vascular endothelium. *J Pharmacol Exp Ther* **309**:825-832.

JPET#163014

- Bodelsson M, Tornebrandt K, Bertilsson IL and Arneklo-Nobin B (1992) Heterogeneity of contractile 5-HT receptors in human hand veins. *Eur J Pharmacol* **219**:455-460.
- Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, Kardia SL, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM and Beer DG (2002) Discordant protein and mRNA expression in lung adenocarcinomas. *Mol Cell Proteomics* **1**:304-313.
- Cohen ML, Fuller RW and Wiley KS (1981) Evidence for 5-HT₂ receptors mediating contraction in vascular smooth muscle. *J Pharmacol Exp Ther* **218**:421-425.
- Cortijo J, Marti-Cabrera M, Bernabeu E, Domenech T, Bou J, Fernandez AG, Beleta J, Palacios JM and Morcillo EJ (1997) Characterization of 5-HT receptors on human pulmonary artery and vein: functional and binding studies. *Br J Pharmacol* **122**:1455-1463.
- Cushing DJ and Cohen ML (1992) Comparison of the serotonin receptors that mediate smooth muscle contraction in canine and porcine coronary artery. *J Pharmacol Exp Ther* **261**:856-862.
- Delesalle C, van Acker N, Claes P, Deprez P, de Smet I, Dewulf J and Lefebvre RA (2008) Contractile effects of 5-hydroxytryptamine (5-HT) in the equine jejunum circular muscle: functional and immunohistochemical identification of a 5-HT_{1A}-like receptor. *Equine Vet J* **40**:313-320.
- Ellis ES, Byrne C, Murphy OE, Tilford NS and Baxter GS (1995) Mediation by 5-hydroxytryptamine_{2B} receptors of endothelium-dependent relaxation in rat jugular vein. *Br J Pharmacol* **114**:400-404.

JPET#163014

Ficarelli E, Bernuzzi G, Tognetti E, Bussolati O, Zucchi A, Adorni D and De Panfilis G (2008) Treatment of chronic venous leg ulcers by platelet gel. *Dermatol Ther* **21 Suppl 1**:S13-17.

Gozlan H, El Mestikawy S, Pichat L, Glowinski J and Hamon M (1983) Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT. *Nature* **305**:140-142.

Greenbaum D, Colangelo C, Williams K and Gerstein M (2003) Comparing protein abundance and mRNA expression levels on a genomic scale. *Genome Biol* **4**:117.

Gul H, Yildiz O, Simsek A, Balkan M, Ersoz N, Cetiner S, Isimer A and Sen D (2003) Pharmacologic characterization of contractile serotonergic receptors in human isolated mesenteric artery. *J Cardiovasc Pharmacol* **41**:307-315.

Guo Y, Xiao P, Lei S, Deng F, Xiao GG, Liu Y, Chen X, Li L, Wu S, Chen Y, Jiang H, Tan L, Xie J, Zhu X, Liang S and Deng H (2008) How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. *Acta Biochim Biophys Sin (Shanghai)* **40**:426-436.

Hile LM, Gibbons MD and Hile DC (2009) Lemierre syndrome complicating otitis externa: case report and literature review. *J Emerg Med.*

Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR and Humphrey PP (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). *Pharmacol Rev* **46**:157-203.

Ishine T, Bouchelet I, Hamel E and Lee TJ (2000) Serotonin 5-HT(7) receptors mediate relaxation of porcine pial veins. *Am J Physiol Heart Circ Physiol* **278**:H907-912.

JPET#163014

Jahnichen S, Glusa E and Pertz HH (2005) Evidence for 5-HT_{2B} and 5-HT₇ receptor-mediated relaxation in pulmonary arteries of weaned pigs. *Naunyn Schmiedebergs Arch Pharmacol* **371**:89-98.

Kaumann AJ, Parsons AA and Brown AM (1993) Human arterial constrictor serotonin receptors. *Cardiovasc Res* **27**:2094-2103.

Kitka T and Bagdy G (2008) **Effect of 5-HT_{2A/2B/2C} receptor agonists and antagonists on sleep and waking in laboratory animals and humans**, in *Serotonin and Sleep: Molecular, Functional and Clinical Aspects* (Monti JM, Pandi-Perumal SR, Jacobs BL and Nutt DJ eds), Birkhäuser Basel Verlag/Switzerland.

Kuhn DM, Wolf WA and Lovenberg W (1980) Review of the role of the central serotonergic neuronal system in blood pressure regulation. *Hypertension* **2**:243-255.

Lim CS, Gohel MS and Davies AH (2008) Is there still a role for basic science research in venous disease? *Phlebology* **23**:147-148.

Linder AE, Beggs KM, Burnett RJ and Watts SW (2009) Body distribution of infused serotonin in rats. *Clin Exp Pharmacol Physiol* **36**:599-601.

Linder AE, Ni W, Szasz T, Burnett R, Diaz J, Geddes TJ, Kuhn DM and Watts SW (2008) A serotonergic system in veins: serotonin transporter-independent uptake. *J Pharmacol Exp Ther* **325**:714-722.

McKune CM and Watts SW (2001) Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling. *J Pharmacol Exp Ther* **297**:88-95.

JPET#163014

- McMullan R, McConville C, Clarke JC, Adams DA and Hedderwick S (2004) Lemierre syndrome: remember the forgotten disease. *Ulster Med J* **73**:123-125.
- Morecroft I, Heeley RP, Prentice HM, Kirk A and MacLean MR (1999) 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT_{1B} receptor. *Br J Pharmacol* **128**:730-734.
- Ni W, Geddes TJ, Priestley JR, Szasz T, Kuhn DM and Watts SW (2008) The existence of a local 5-hydroxytryptaminergic system in peripheral arteries. *Br J Pharmacol* **154**:663-674.
- Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Brancheck T and Edvinsson L (1999) Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. *Eur J Pharmacol* **372**:49-56.
- Pascarella L, Schmid-Schonbein GW and Bergan J (2005) An animal model of venous hypertension: the role of inflammation in venous valve failure. *J Vasc Surg* **41**:303-311.
- Rapport MM, Green AA and Page IH (1948) Serum vasoconstrictor, serotonin; isolation and characterization. *J Biol Chem* **176**:1243-1251.
- Russell A, Banes A, Berlin H, Fink GD and Watts SW (2002) 5-Hydroxytryptamine(2B) receptor function is enhanced in the N(omega)-nitro-L-arginine hypertensive rat. *J Pharmacol Exp Ther* **303**:179-187.
- Schachner T, Laufer G and Bonatti J (2006) In vivo (animal) models of vein graft disease. *Eur J Cardiothorac Surg* **30**:451-463.

JPET#163014

- Titeler M, Lyon RA, Davis KH and Glennon RA (1987) Selectivity of serotonergic drugs for multiple brain serotonin receptors. Role of [3H]-4-bromo-2,5-dimethoxyphenylisopropylamine ([3H]DOB), a 5-HT₂ agonist radioligand. *Biochem Pharmacol* **36**:3265-3271.
- Ullmer C, Schmuck K, Kalkman HO and Lubbert H (1995) Expression of serotonin receptor mRNAs in blood vessels. *FEBS Lett* **370**:215-221.
- Vialli M and Erspamer V (1937) Ricerche sul secreto delle cellule enterocromaffini *Cell and Tissue Research* **27**:81-99.
- Villalon CM and Centurion D (2007) Cardiovascular responses produced by 5-hydroxytryptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications. *Naunyn Schmiedebergs Arch Pharmacol* **376**:45-63.
- Wacker MJ and Godard MP (2005) Analysis of one-step and two-step real-time RT-PCR using SuperScript III. *J Biomol Tech* **16**:266-271.
- Watts SW (2002) Serotonin-induced contraction in mesenteric resistance arteries: signaling and changes in deoxycorticosterone acetate-salt hypertension. *Hypertension* **39**:825-829.
- Watts SW and Cohen ML (1999) Vascular 5-HT receptors: pharmacology and pathophysiology of 5-HT_{1B}, 5-HT_{1D}, 5-HT_{1F}, 5-HT_{2B} and 5-HT₇ receptors. *Neurotransmissions* **15**:3-15.
- Watts SW and Thompson JM (2004) Characterization of the contractile 5-hydroxytryptamine receptor in the renal artery of the normotensive rat. *J Pharmacol Exp Ther* **309**:165-172.

JPET#163014

Watts SW, Yang P, Banes AK and Baez M (2001) Activation of Erk mitogen-activated protein kinase proteins by vascular serotonin receptors. *J Cardiovasc Pharmacol* **38**:539-551.

Yildiz O, Gul H, Ozgok Y, Onguru O, Kilciler M, Aydin A, Isimer A and Harmankaya AC (2003) Increased vasoconstrictor reactivity and decreased endothelial function in high grade varicocele; functional and morphological study. *Urol Res* **31**:323-328.

JPET#163014

Footnotes

a) This work was supported by the National Institutes of Health National Heart, Lung and Blood Institute [Grant 81115, SWW]; and Fundação de Apoio à Pesquisa Científica e Tecnológica do Estado de Santa Catarina and Conselho Nacional de Desenvolvimento Científico e Tecnológico [Grant 2371/090, AEL]. AEL was a recipient of an American Heart Association Postdoctoral Fellowship [Grant 0725729Z].

b) Reprint requests

A. Elizabeth Linder

Department of Pharmacology

Universidade Federal de Santa Catarina

University Campus, Trindade

Biological Sciences Center, Block "D"

Florianopolis, Santa Catarina, Brazil

Phone: 55 (48) 3721.9491

Fax: 55 (48) 3721.9491

Email: beth.linder@ccb.ufsc.br

JPET#163014

Legends for Figures

Figure 1: Effect of 5-HT receptor agonists in contracting endothelium-intact rat jugular vein rings. Concentration-effect curves for thirteen 5-HT receptor agonists were constructed. Agonists are divided into agonists that are potent and cause a large maximum contraction (A) and agonists that are less potent and cause a smaller maximum contraction than 5-HT (B). Points represent means \pm S.E.M. of the contraction expressed as percentage of KCl (60 mM)-induced contraction of (n) experiments.

Figure 2: Effect of 5-HT_{2A/2C} receptor antagonist ketanserin on 5-HT-induced contraction in rat jugular vein. The concentration-effect curve obtained with 5-HT was evaluated in the absence (control) and in the presence of ketanserin (30 nM). Points represent means \pm SEM of the contraction expressed as percentage of KCl (60 mM)-induced contraction of (n) experiments. * P < 0.05 vs. control.

Figure 3: Effect of 5-HT receptor antagonists on 5-HT-induced contraction of rat jugular vein. Concentration-effect to 5-HT was performed in the absence (control) and in the presence of the antagonists for the receptors 5-HT_{1A} (WAY100135; A-B), 5-HT_{1B} (GR127935; C-D), 5-HT_{2B} (LY266097; E-F), and 5-HT₇ (SB269970; G-H). Points represent means \pm SEM of the contraction expressed as percentage of KCl (60 mM)-induced contraction of (n) experiments. * P < 0.05 vs. control.

JPET#163014

Figure 4: Effect of the 5-HT_{1A} and 5-HT_{2B} receptor antagonists on the contraction induced by the 5-HT_{1A}, 5-HT_{1A/1B} and 5-HT_{2B} receptor agonists in rat jugular vein. The concentration-effect curves induced by the agonist of the 5-HT_{1A} receptor 8-OH-DPAT (A), the 5-HT_{1A/1B} receptor RU24969 (B) and the 5-HT_{2B} receptor BW723C86 were evaluated in the absence (control) and in the presence of antagonists of the 5-HT_{1A} receptor WAY100135 (3x10⁻⁷ M) (A, B) and the 5-HT_{2B} receptor LY266097 (10⁻⁸ M) (C). Points represent means ± SEM of the contraction expressed as percentage of KCl (60 mM)-induced contraction of (n) experiments. * P < 0.05 vs. control.

Figure 5: Effect of ketanserin on the contraction induced by 5-HT receptor agonists in rat jugular vein. The concentration-effect curve induced by 8-OH-DPAT (A), RU24969 (B) and BW723C86 (C) was evaluated in the absence (control) and in the presence of ketanserin (30 nM). Points represent means ± SEM of the contraction expressed as percentage of KCl (60 mM)-induced contraction of (n) experiments. * P < 0.05 vs. control.

Figure 6: RT-PCR analysis of 5-HT receptors mRNA expression in rat jugular vein. Data are means ± SEM for n = 5 measurements expressed as the change from B2m (2^{-ΔΔCt}).

JPET#163014

Table 1: Pharmacological parameters for 5-HT receptor agonist-induced contraction in endothelium-intact rat jugular vein.

Agonist	pD ₂ =-log EC ₅₀ [M]	Maximum Effect (mg)	N
5-HT	6.65 ± 0.17	729 ± 83.4	13
α-methyl-5-HT	7.23 ± 0.05	777 ± 108.5	5
DOI	7.76 ± 0.12	631 ± 59.1	8
5-methoxytryptamine	7.19 ± 0.04	627 ± 35.8	6
5-CT	6.52 ± 0.40	502 ± 30.53	5
BRL5443	7.32 ± 0.03	482 ± 12.4	4
8-OH-DPAT	5.58 ± 0.06	329 ± 23.4	5
BW723C86	6.17 ± 0.10	310 ± 47.8	8
RU24969	6.38 ± 0.10	229 ± 23.7	6
LP44	n/a	155 ± 31.8	8
Sumatriptan	n/a	10 ± 3.41	5
Zacopride	n/a	n/a	4
EMD386088	n/a	n/a	6

n/a Could not be obtained; N, number of experiments.

Figure 1





Figure 2






Figure 3










Figure 6

